Transdermal (and related transmucosal) drug delivery is a well-established accepted route of administration for therapeutically beneficial medicines. There is no potential limit for the therapeutic area for development of transdermal systems. Some therapeutic areas stand out, including sex hormones and pain management, due to the successful combination of the individual drug molecules and available product technologies. The potential benefits that may be achieved using transdermal delivery include continuous, controlled release and absorption of medication into the body, avoiding presystemic metabolism that may occur following oral dosing, including both intestinal and hepatic first-pass metabolism, improving patient compliance by offering more convenient dosing regimens , such as once or twice weekly dosing, and the ability to quickly discontinue treatment by removal of the system.
This report, World Markets for Transdermal Drug Delivery is a comprehensive look at the transdermal/transmucosal drug delivery market is divided into two sections. The first section encompasses the pharmaceutical products that utilize the drug delivery technology. The second section encompasses drug delivery technology and the revenues earned from licensing that technology. Because drug delivery technology is an integral part of sales of pharmaceuticals and drug delivery technology cannot exist without pharmaceuticals, revenues have been reported that include pharmaceutical sales for products utilizing that technology.
This market is divided into two segments:
- Market Size and Forecast for Transdermal Drug Delivery
- Market Size and Forecast for Transmucosal Drug Delivery
- Market Breakout by Region (US, Europe, Japan, ROW)
- Review of Products on the Market
- Market Breakout by Disease Treated (Cardiovascular, Hormones, Pain Management, Smoking Cessation, Other)
- Market Breakout by Technology Revenues and Pharmaceutical Component Revenues
- Profiles of Companies in the Market
The research conducted by Kalorama included comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. New technologies, market developments, and research and development trends and expenditures were identified through patent and database searches, as well as via interviews with key personnel. Person-to-person and telephone interviews were the primary method of gathering information. E-mail correspondence was also used in the interview process. Interviews with 18 key industry officials, trade association representatives, consultants, healthcare providers, and government personnel were compiled to form the primary basis of information—particularly revenue and market share data—presented in this report.
All market data pertain to the worldwide market at the manufacturers’ level and presented in U.S. dollars. The base year for data was 2012. Historical data are provided for 2010 through 2011, with forecast data provided for 2013 through 2017. Compound annual growth rates (CAGR) are provided for the 2010-2012, 2012-2017, and 2010–2017 periods.
The following companies are profiled in this report
- 3M Pharmaceuticals
- Access Pharmaceuticals, Inc.
- Acrux Limited
- ALZA Corporation
- Antares Pharma, Inc.
- Apricus BioSciences
- Aveva Drug Delivery Systems
- Generex Biotechnology Corporation
- Inovio Pharmaceuticals, Inc.
- Labtec GmbH
- Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG)
- NITTO DENKO CORPORATION
- Noven Pharmaceuticals, Inc.
- Pantec Biosolutions AG
- TEVA Pharmaceutical Industries Ltd.
- Zosano Pharma